Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
05 oct. 2022 08h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced six...
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors
05 avr. 2022 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 05, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced...
Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607
29 mars 2022 16h01 HE
|
Nurix Therapeutics, Inc.
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types The ILAP aims to accelerate the time to market for innovative medicines that address the...
Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting
08 mars 2022 16h47 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical...
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
12 nov. 2021 07h09 HE
|
Nurix Therapeutics, Inc.
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) --...
Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference
12 nov. 2021 07h07 HE
|
Nurix Therapeutics, Inc.
DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL Michael T. Lotze, Nurix’s chief cellular...